49 results about "Ascomycin" patented technology

A formulation to treat ocular conditions such as dry eye disease, as well as other conditions, is disclosed. Rapamycin and / or ascomycin is administered intraocularly, such as by topical application, injection into the eye, or implantation in or on the eye. For example, a topical administration may contain between about 50 pg / ml drug to about 50 μg / ml drug in a formulation which may be applied at bedtime or throughout the day. For injection, a dose of about 50 pg / ml to about 200 μg / ml may be used. Rapamycin and / or ascomycin may also be administered in milligram quantities as a surgical implant, for example, in a diffusible walled reservoir sutured to the wall of the sclera, or may be contained within an inert carrier such as microspheres or liposomes to provide a slow-release drug delivery system.

Ocular solutions containing at least one macrolide antibiotic and / or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the need for a subsequent surgery. The solution may be one that is invasively administered, for example, an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be one that is non-invasively or topically administered in the form of drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions. The solution may contain a supratherapeutic concentration of agent(s) so that a therapeutic concentration of a topically administered solution accumulates in a diseased ocular structure sufficient to treat the disease.

A formulation to treat ocular conditions such as dry eye disease, as well as other conditions, is disclosed. Rapamycin and / or ascomycin is administered intraocularly, such as by topical application, injection into the eye, or implantation in or on the eye. For example, a topical administration may contain between about 50 pg / ml drug to about 50 μg / ml drug in a formulation which may be applied at bedtime or throughout the day. For injection, a dose of about 50 pg / ml to about 200 μg / ml may be used. Rapamycin and / or ascomycin may also be administered in milligram quantities as a surgical implant, for example, in a diffusible walled reservoir sutured to the wall of the sclera, or may be contained within an inert carrier such as microspheres or liposomes to provide a slow-release drug delivery system.

Containing at least one macrolide antibiotic and / or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the need for a subsequent surgery. The solution may be one that is invasively administered, for example, an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be one that is non-invasively or topically administered in the form of drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions.

The invention is a simple process for separation of tacrolimus and its analogues, ascomycin and tsucubamycin B and preparation of enough pure crystalline tacrolimus. The process takes advantage of surprising properties of tacrolimus and involves extraction, purification and crystallization to produce purified crystalline tacrolimus.

The invention provides ophthalmic compositions and methods treating the symptoms of ocular allergies. The principle active ingredient in these compositions and methods is macrolide compound, such as tacrolimus, ascomycin and rapamycin and their derivatives. Optimal concentrations and dosing regimens are provided.

The invention teaches derivatives of ascomycin and methods of preparing immunogens and other conjugates useful in immunoassays for quantitatively measuring concentrations of tacrolimus in patient specimens. Antibodies produced from the disclosed immunogens capable of binding to tacrolimus with cross-reactivity of no more than 5% with each of 15-O-demethyl tacrolimus, 31-O-demethyl tacrolimus, and 13,31-O-didemethyl tacrolimus, less than 40% with 13-O-demethyl tacrolimus, and less than 1% with cyclosporin, rapamycin, mycophenolic acid, prednisone, hydrocortisol, and prednisolone are described. Further, immunoassays for measuring the concentration of tacrolimus using such antibodies are taught.

The invention relates to a bactericidal composition. Active components of the composition contain picoxystrobin and ascomycin, wherein the weight ratio of the picoxystrobin to the ascomycin ranges from (1 to 1) to (1 to 100). The invention further relates to a method for preventing and controlling agricultural fungal diseases by utilizing the composition and application of the composition.

The invention discloses a method for promoting microbes to synthesize ascomycin by using an exogenous additive and a preparation of a culture medium, and belongs to the technical field of biologic synthesis of ascomycins. The method is characterized in that, on the basis of the characteristic that the ascomycin biologic synthesis process refers to the assembly of various precursors, at the beginning of the aerobic fermentation or in the process of aerobic fermentation, 0.5-3.0 g of shikimic acid, 0.5-3.0 g of isoleucine and 1-5 g of soybean oil are added in every one liter of a culture mediumfor enhancing the accumulation of ascomycin synthesis precursors DHCHC, malonyl and methyl malonyl, promoting the metabolism of the ascomycin synthesis pathway, thereby improving the yield of the ascomycin. The method provided by the invention is simple to operate and is low in cost because no extra device and labor is increased and only low additional investment is input; in the step of fermenting and culturing streptomyces hygroscopicus ascomycota subspecies, the fermenting unit of the ascomycin is improved by 55.9-114.7% as compared with a control group.